Involvement of carboxylesterase 1 and 2 in the hydrolysis of mycophenolate mofetil

Drug Metabolism and Disposition

Volumn 38, Issue 12, 2010, Pages 2210-2217

  Fujiyama, Nobuhiro ^a   Miura, Masatomo ^a   Kato, Shoutaro ^a   Sone, Tomomichi ^b   Isobe, Masakazu ^b   Satoh, Shigeru ^c  

^a AKITA UNIVERSITY HOSPITAL   (Japan)

^b SETSUNAN UNIVERSITY   (Japan)

^c AKITA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

4 NITROPHENYL PHOSPHATE; CARBOXYLESTERASE; CARBOXYLESTERASE 1; CARBOXYLESTERASE 2; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD; CATALYSIS; CELL STRAIN COS1; CENTRIFUGATION; CONTROLLED STUDY; CYTOSOL; DRUG ACTIVATION; DRUG HALF LIFE; DRUG HYDROLYSIS; ENZYME ACTIVITY; ERYTHROCYTE; FEMALE; HUMAN; HUMAN CELL; IC 50; INTESTINE; LIVER CYTOSOL; MALE; MICROSOME; PLASMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SUPERNATANT;

ADULT; ANIMALS; CARBOXYLESTERASE; CARBOXYLIC ESTER HYDROLASES; CERCOPITHECUS AETHIOPS; COS CELLS; FEMALE; HUMANS; HYDROLYSIS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; RECOMBINANT PROTEINS;

EID: 78649540887     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.110.034249     Document Type: Article

References (27)

1. Allison AC and Eugui EM (1993) Immunosuppressive and other effects of mycophenolic acid and an ester prodrug, mycophenolate mofetil. Immunol Rev 136:5-28.
2. Armstrong VW, Tenderich G, Shipkova M, Parsa A, Koerfer R, Schröder H, and Oellerich M (2005) Pharmacokinetics and bioavailability of mycophenolic acid after intravenous administration and oral administration of mycophenolate mofetil to heart transplant recipients. Ther Drug Monit 27:315-321.
3. Baldelli S, Merlini S, Perico N, Nicastri A, Cortinovis M, Gotti E, Remuzzi G, and Cattaneo D (2007) C-440T/T-331C polymorphisms in the UGT1A9 gene affect the pharmacokinetics of mycophenolic acid in kidney transplantation. Pharmacogenomics 8:1127-1141.
4. Bernard O and Guillemette C (2004) The main role of UGT1A9 in the hepatic metabolism of mycophenolic acid and the effects of naturally occurring variants. Drug Metab Dispos 32:775-778.
5. Bullingham R, Monroe S, Nicholls A, and Hale M (1996) Pharmacokinetics and bioavailability of mycophenolate mofetil in healthy subjects after single-dose oral and intravenous administration. J Clin Pharmacol 36:315-324.
6. Bullingham RE, Nicholls AJ, and Kamm BR (1998) Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet 34:429-455.
7. Costello PB and Green FA (1983) Identification and partial purification of the major aspirin hydrolyzing enzyme in human blood. Arthritis Rheum 26:541-547.
8. Fujiyama N, Miura M, Satoh S, Inoue K, Kagaya H, Saito M, Habuchi T, and Suzuki T (2009) Influence of carboxylesterase 2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Xenobiotica 39:407-414.
9. Heymann E and Krisch K (1967) Phosphoric acid-bis-(p-nitro-phenylester), a new inhibitor of microsomal carboxylesterases. Hoppe Seylers Z Physiol Chem 348:609-619.
10. Kuypers DR, Naesens M, Vermeire S, and Vanrenterghem Y (2005) The impact of uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) gene promoter region single-nucleotide polymorphisms T-275A and C-2152T on early mycophenolic acid dose-interval exposure in de novo renal allograft recipients. Clin Pharmacol Ther 78:351-361. (Pubitemid 41393670)
11. La Du BN and Snady H (1971) Esterases of human tissues, in Handbook of Experimental Pharmacology, Concepts in Biochemical Pharmacology, Part 2, (Brodie BB and Gillette JR eds) vol 28, pp 477-499, Springer-Verlag, New York.
12. Lee WA, Gu L, Miksztal AR, Chu N, Leung K, and Nelson PH (1990) Bioavailability improvement of mycophenolic acid through amino ester derivatization. Pharm Res 7:161-166.
13. Medda S and Proia RL (1992) The carboxylesterase family exhibits C-terminal sequence diversity reflecting the presence or absence of endoplasmic-reticulum-retention sequences. Eur J Biochem 206:801-806.
14. Ott P, Jenny B, and Brodbeck U (1975) Multiple molecular forms of purified human erythrocyte acetylcholinesterase. Eur J Biochem 57:469-480.
15. Oertel J, Wirthmüller R, and Kastner M (1983) Alpha naphthyl acetate esterase in human blood cells with different molecular weights. Blut 46:101-106.
16. Pescovitz MD, Conti D, Dunn J, Gonwa T, Halloran P, Sollinger H, Tomlanovich S, Weinstein S, Inokuchi S, Kiberd B, et al. (2000) Intravenous mycophenolate mofetil: safety, tolerability, and pharmacokinetics. Clin Transplant 14:179-188.
17. Picard N, Ratanasavanh D, Prémaud A, Le Meur Y, and Marquet P (2005) Identification of the UDP-glucuronosyltransferase isoforms involved in mycophenolic acid phase II metabolism. Drug Metab Dispos 33:139-146.
18. Pindel EV, Kedishvili NY, Abraham TL, Brzezinski MR, Zhang J, Dean RA, and Bosron WF (1997) Purification and cloning of a broad substrate specificity human liver carboxylesterase that catalyzes the hydrolysis of cocaine and heroin. J Biol Chem 272:14769-14775. (Pubitemid 27251744)
19. Robbi M and Beaufay H (1987) Biosynthesis of rat liver pI-6.1 esterase, a carboxylesterase of the cisternal space of the endoplasmic reticulum. Biochem J 248:545-550.
20. Satoh T, Taylor P, Bosron WF, Sanghani SP, Hosokawa M, and La Du BN (2002) Current progress on esterases: from molecular structure to function. Drug Metab Dispos 30:488-493.
21. Slatter JG, Su P, Sams JP, Schaaf LJ, and Wienkers LC (1997) Bioactivation of the anticancer agent CPT-11 to SN-38 by human hepatic microsomal carboxylesterases and the in vitro assessment of potential drug interactions. Drug Metab Dispos 25:1157-1164.
22. Staatz CE and Tett SE (2007) Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. Clin Pharmacokinet 46:13-58.
23. Tabata T, Katoh M, Tokudome S, Hosakawa M, Chiba K, Nakajima M, and Yokoi T (2004a) Bioactivation of capecitabine in human liver: involvement of the cytosolic enzyme on 5′-deoxy-5-fluorocytidine formation. Drug Metab Dispos 32:762-767. (Pubitemid 38821879)
24. Tabata T, Katoh M, Tokudome S, Nakajima M, and Yokoi T (2004b) Identification of the cytosolic carboxylesterase catalyzing the 5′-deoxy-5-fluorocytidine formation from capecitabine in human liver. Drug Metab Dispos 32:1103-1110.
25. Taketani M, Shii M, Ohura K, Ninomiya S, and Imai T (2007) Carboxylesterase in the liver and small intestine of experimental animals and human. Life Sci 81:924-932.
26. Xu G, Zhang W, Ma MK, and McLeod HL (2002) Human carboxylesterase 2 is commonly expressed in tumor tissue and is correlated with activation of irinotecan. Clin Cancer Res 8:2605-2611.
27. Yamaori S, Fujiyama N, Kushihara M, Funahashi T, Kimura T, Yamamoto I, Sone T, Isobe M, Ohshima T, Matsumura K, et al. (2006) Involvement of human blood arylesterases and liver microsomal carboxylesterases in nafamostat hydrolysis. Drug Metab Pharmacokinet 21:147-155.